Baxter's Growth Sustainable Through 2013/2014 According To Goldman

Goldman Sachs has published a research report for Baxter International Inc. (NYSE: BAX).

In the report, Goldman writes "We attended Biogen Idec's Hemophilia R&D Roundtable in Cambridge, MA, to get an update on the Hemophilia market as well as new recombinant technologies. We came away comfortable with our view that Baxter's Recombinant business (16% of sales) has no intermediate-term risk to competitive products, as next-generation recombinants will likely not come to market until 2013/2014 at the earliest. In addition, our diligence suggests that hemophilia is a patient-driven market and that Baxter's name brand is well affiliated with treatment."

Goldman maintains its Buy rating and $58 price target.

Baxter International Inc. closed yesterday at $47.95.

Don't miss these trading ideas!